PRESS-RELEASE ·Filed Apr 29, 2026
Press release · Earnings
Actionable Insight • Neutral
Monitor for upcoming clinical trial catalysts or financing events; no immediate trading signal from this earnings release.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60Entry
$0.7800
T+0 close · Apr 29, 2026 · via day close
Latest settled
+51.28%
T+60 · $1.18
Vs SPY
+48.17%
α at T+60
Horizons
All settled
through T+60
- T+0 · Apr 30 $0.7800entry
- T+1 · 7mo ago +28.21%α +27.99% · $1.00
- T+5 · 6mo ago +29.49%α +27.76% · $1.01
- T+20 · 6mo ago +28.21%α +22.98% · $1.00
- T+60 · 4mo ago +51.28%α +48.17% · $1.18
Price Chart
Loading chart...
How similar events traded
Executive Summary
Vaccinex released financial results for the year ended December 31, 2025, reporting an EPS of -$1.09 for Q3 2023, which was in line with consensus estimates. As a clinical-stage biotech with no revenue, the filing is routine and lacks material financial surprises or guidance changes.
Key Financial Metrics
EPS
−$1.09
Revenue
$0.00
est $0.00
Rating
in line
Key Facts
- EPS of -$1.09 for Q3 2023, in line with consensus
- No revenue reported for the period
- Clinical-stage company with no approved products or revenue stream
- Financial statements posted on company website
Financial Impact
No material financial impact; clinical-stage biotech with no revenue and EPS in line with expectations
eps
Risk Factors
- No revenue or near-term commercialization path
- Dependence on future financing for clinical development
Market Snapshot
Exchange
OTC
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284388 |
US Market Status
Market Closed · Opens in 6h 31m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers